Oncternal Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Oncternal Therapeutics generated cash of -$32,164,000, which is more than the previous year. Cash used in financing activities reached the amount of $1,068,000 last year. Net change in cash is therefore -$30,445,000.
Cash Flow
| 2014 | -28.75M | -31.22M | 63.33M |
|---|---|---|---|
| 2015 | -20.03M | 16.21M | 0 |
| 2016 | -20.77M | 2.15M | 13.48M |
| 2017 | -23.46M | -15.12M | 45.49M |
| 2018 | -39.34M | 27.88M | 23.90M |
| 2019 | -16.74M | 16.13M | 15K |
| 2020 | -17.49M | 0 | 114.18M |
| 2021 | -26.58M | 0 | 617K |
| 2022 | -36.70M | -26.49M | 9.57M |
| 2023 | -32.16M | 651K | 1.06M |
ONCT Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 37.14M | 90.76M | 116.73M | 20.05M | 20.64M | 15.81M | 8.91M | 14.05M | 17.88M | 14.52M |
Operating activities | ||||||||||
Net income | -39.47M | -44.17M | -31.33M | -17.22M | -34.18M | -38.41M | -30.43M | -17.72M | -18.70M | -39.41M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | -75K | 169K | 150K | 0 | 46K | 47K | 28K | 43K | 102K |
Stock-based compensation expense | 7.5M | 7.43M | 5.87M | 1.55M | 507K | 0 | 3.15M | 2.95M | 2.62M | 4.42M |
| Deferred income tax benefit | 7.5M | 7.43M | 5.87M | 1.55M | 507K | 0 | 3.15M | 2.95M | 2.62M | 4.42M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -1.76M | 958K | 816K | 272K | -4.76M | 675K | 1.38M | 838K | -130K | -296K |
Cash generated by operating activities | -32.16M | -36.70M | -26.58M | -17.49M | -16.74M | -39.34M | -23.46M | -20.77M | -20.03M | -28.75M |
Investing activities | ||||||||||
Purchases Of Investments | -64.34M | -26.49M | 0 | 0 | 0 | -44.15M | -39.28M | -35.40M | -55.21M | -41.90M |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | 0 | -2K | -90K | -4K | -5K |
Acquisitions Net | 0 | 0 | 0 | 0 | 16.13M | 0 | -24.15M | -37.64M | -71.43M | -10.69M |
Cash generated by investing activities | 651K | -26.49M | 0 | 0 | 16.13M | 27.88M | -15.12M | 2.15M | 16.21M | -31.22M |
Financing activities | ||||||||||
Common Stock Issued | 1.22M | 9.58M | 617K | 113.87M | 1K | 24.47M | 45.64M | 13.69M | 0 | 63.94M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -156K | -3K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -301K | 0 | 0 | 0 | 0 | 0 | -2K |
Cash used in financing activities | 1.06M | 9.57M | 617K | 114.18M | 15K | 23.90M | 45.49M | 13.48M | 0 | 63.33M |
Net Change In Cash | -30.44M | -53.62M | -25.97M | 96.68M | -594K | 12.44M | 6.90M | -5.14M | -3.82M | 3.35M |
Cash at end of period | 6.69M | 37.14M | 90.76M | 116.73M | 20.05M | 28.25M | 15.81M | 8.91M | 14.05M | 17.88M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |